SOUTH SAN FRANCISCO, Calif., November 16, 2026 — California Life Sciences (CLS) today announced the election of four new members to its Board of Directors: Pooja Agarwal, PhD; Jennifer Rhodes; Bob Smith; Marc Taub, PhD; and Christopher Walsh.
“We are pleased to welcome five outstanding new members to our Board of Directors,” said Mike Guerra, President and CEO of CLS. “Together, they bring deep expertise in research and development, government affairs, patient advocacy, and legal strategy, and I am confident that their experience will help us better serve our members no matter where they are in their journey. I look forward to working alongside them as we continue building the ecosystem that lets California’s life sciences companies grow.”
Pooja Agarwal, PhD
Pooja Agarwal, PhD, serves as Vice President and Head of Enzymes and Metabolic Disease Research, Therapeutic Modalities, and SRC Laboratory Operations at BioMarin. In this role, she provides strategic leadership for the company’s metabolic disease research portfolio, guiding the advancement of innovative therapies across phenylketonuria (PKU), lysosomal storage disorders, and other rare genetic diseases. She partners closely with leaders across Research and Early Development, Clinical Development, Commercial, Medical Affairs, Patient Advocacy, and Business Development to shape long-term portfolio strategy, accelerate pipeline execution, and strengthen BioMarin’s leadership in rare disease innovation.
Jennifer Rhodes
Jennifer Rhodes is the Executive Vice President, Chief Legal Officer and Secretary at Acadia and has been with the Company since January 2024. Prior to joining the Company, Ms. Rhodes served Angion Biomedica Corp. as its Executive Vice President and Chief Business Officer from March 2022 to July 2023, and as General Counsel, Chief Compliance Officer and Corporate Secretary from January 2020 to March 2022. Ms. Rhodes previously served as General Counsel and Corporate Secretary at Adamas Pharmaceuticals, Inc. from April 2016 until January 2020, during which time she also served as Chief Compliance Officer since August 2016 and Chief Business Officer since January 2017.
Bob Smith
Bob Smith has 30 years of commercial pharmaceutical/biotech industry experience, with deep expertise in rare diseases, particularly pulmonary arterial hypertension (PAH). He currently serves as Chief Commercial Officer at Gossamer Bio. Prior to joining Gossamer, he served in a senior leadership role at Merck & Co. preparing for the launch of sotatercept. He also founded LTM Pharma Consulting, advising pre-commercial rare disease companies on commercial strat-egy, launch readiness, and organizational development.
Marc Taub, PhD
Marc Taub, PhD, is Vice President of Technical Operations for Abbott’s diabetes care and biowearables businesses, overseeing global research and development, medical, and clinical affairs. Based in Alameda, California, he has played a key role in pioneering biowearables like the FreeStyle Libre portfolio, world-leading glucose monitoring technology that has transformed care for people living with diabetes. This same technology powers Lingo, a consumer biowearable designed to help users track glucose for healthier habits and overall well-being.
Christopher Walsh
Christopher Walsh is General Counsel of Denali Therapeutics. As a strategic partner to Denali’s management team and Board, Chris leads the company’s legal function, overseeing the legal strategy across corporate governance, public-company securities and disclosures, collaborations and contracts, intellectual property, commercial readiness, employment, and litigation, in support of Denali’s mission.
###
About California Life Sciences: California Life Sciences (CLS) is the state’s leading advocate for the life sciences. We represent the entire innovation ecosystem, from startups and global companies to research institutions and service providers. We champion smart policy, foster strategic connections, and deliver resources that help life sciences companies grow and thrive. Based in the global epicenter of innovation, we work to ensure that the discoveries made here translate into healthier lives everywhere.
For media inquiries, please contact:
Katie Kiss
Senior Director, Marketing
(858) 456-8894
[email protected]
